Assessing the efficacy‐effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population‐based, real‐world …
CM Phillips, A Parmar, H Guo, D Schwartz… - Cancer, 2020 - Wiley Online Library
Background Although increasing evidence has suggested that an efficacy‐effectiveness gap
exists between clinical trial (CT) and real‐world evidence (RWE), to the authors' knowledge …
exists between clinical trial (CT) and real‐world evidence (RWE), to the authors' knowledge …
Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
CM Cramer-van der Welle, BJM Peters… - European …, 2018 - Eur Respiratory Soc
The divergence between clinical trial results and real-world outcomes is largely unknown for
many cancer types. The present study aims overall to assess the efficacy–effectiveness gap …
many cancer types. The present study aims overall to assess the efficacy–effectiveness gap …
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
PA Kaufman, E Neuberger, NRM Schwartz… - Frontiers in …, 2023 - frontiersin.org
Background Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed
therapy approved in combination with trastuzumab and capecitabine for use in patients with …
therapy approved in combination with trastuzumab and capecitabine for use in patients with …
Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies
The number of trials conducted and the number of patients per trial are typically small in
paediatric clinical studies. This is due to ethical constraints and the complexity of the medical …
paediatric clinical studies. This is due to ethical constraints and the complexity of the medical …
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
Background It has been suggested that the results from fragile trials are less likely to
translate into benefit in routine clinical practice. Methods We searched the Food and Drug …
translate into benefit in routine clinical practice. Methods We searched the Food and Drug …
KẾT QUẢ ĐIỀU TRỊ CHUỖI HÓA TRỊ VÀ THUỐC KHÁNG EGFR TRÊN BỆNH NHÂN UNG THƯ PHỔI GIAI ĐOẠN MUỘN
TĐ Lê, TTH Bùi - Tạp chí Y học Việt Nam, 2022 - tapchiyhocvietnam.vn
Tóm tắt Mục tiêu: Đánh giá kết quả điều trị chuỗi hóa trị và thuốc kháng EGFR trên bệnh
nhân ung thư phổi giai đoạn muộn. Đối tượng nghiên cứu: BN được chẩn đoán UTPTBN …
nhân ung thư phổi giai đoạn muộn. Đối tượng nghiên cứu: BN được chẩn đoán UTPTBN …
[PDF][PDF] TRONG § IÒU TRÞ UNG TH¦ phæi BIÓU M¤ TUYÕN Giai® o¹n muén
BỘY TẾ, HÀ LÊ THU - sdh.hmu.edu.vn
Đảng ủy, Ban giám hiệu, Phòng quản lý đào tạo Sau đại học, Bộ môn Ung thư-Trường Đại
học Y Hà Nội. Ban giám đốc Bệnh viện K, Bệnh viện Ung bướu Hà Nội, Trung tâm Y học hạt …
học Y Hà Nội. Ban giám đốc Bệnh viện K, Bệnh viện Ung bướu Hà Nội, Trung tâm Y học hạt …
Modèles statistiques pour l'extrapolation de l'information adulte à l'enfant dans les essais cliniques
C Petit - 2017 - theses.hal.science
Cette thèse est consacrée aux méthodes statistiques d'extrapolation dans les essais de
recherche de dose en pédiatrie. Dans un premier temps, nous réalisons une revue …
recherche de dose en pédiatrie. Dans un premier temps, nous réalisons une revue …
Future treatment of nsclc patients with new egfr targeting drugs
S de Waard - 2014 - fse.studenttheses.ub.rug.nl
The treatment of non-small cell lung carcinoma (NSCLC) patients with epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKI's), such as gefitinib and erlotinib, was …
factor receptor tyrosine kinase inhibitors (EGFR-TKI's), such as gefitinib and erlotinib, was …
[PDF][PDF] Vandetanib–
E Nutzenbewertung - 2013 - iqwig.de
Die Verantwortung für die vorliegende Bewertung und für das Bewertungsergebnis liegt
ausschließlich beim IQWiG. Die Bewertung wird zur Veröffentlichung an den G-BA …
ausschließlich beim IQWiG. Die Bewertung wird zur Veröffentlichung an den G-BA …